The continuing popularity of SUs as second-line drugs for diabetes can be explained not only by their long-established track record as insulin secretagogues but also by several endpoints, including efficacy, treatment adherence, decline in -cell function, tolerability over time, and affordability
Zheng Y, Song Y, Han Q, Liu W, Xu J, Yu Z, Zhang R, Li N
to reduce the risk of serious kidney problems in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD)
Micelles can be also engineered to release their payload under specific conditions, improving the precision and effectiveness of treatments [113]
Using them in the same routine is often debated
This makes it a valuable research compound for those focusing on molecular biology and cellular communication